[go: up one dir, main page]

MA28798B1 - Dérivés de triazolopyridinylsufanyle servant d'inhibiteurs de kinase MAP P38 - Google Patents

Dérivés de triazolopyridinylsufanyle servant d'inhibiteurs de kinase MAP P38

Info

Publication number
MA28798B1
MA28798B1 MA29676A MA29676A MA28798B1 MA 28798 B1 MA28798 B1 MA 28798B1 MA 29676 A MA29676 A MA 29676A MA 29676 A MA29676 A MA 29676A MA 28798 B1 MA28798 B1 MA 28798B1
Authority
MA
Morocco
Prior art keywords
triazolopyridinylsufanyl
map
derivatives
kinase inhibitors
kinase
Prior art date
Application number
MA29676A
Other languages
English (en)
Inventor
John Paul Mathias
David Simon Millan
Russell Andrew Lewthwaite
Christopher Phillips
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0418015A external-priority patent/GB0418015D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA28798B1 publication Critical patent/MA28798B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
MA29676A 2004-08-12 2007-02-12 Dérivés de triazolopyridinylsufanyle servant d'inhibiteurs de kinase MAP P38 MA28798B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0418015A GB0418015D0 (en) 2004-08-12 2004-08-12 New compounds
US69155905P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
MA28798B1 true MA28798B1 (fr) 2007-08-01

Family

ID=35783420

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29676A MA28798B1 (fr) 2004-08-12 2007-02-12 Dérivés de triazolopyridinylsufanyle servant d'inhibiteurs de kinase MAP P38

Country Status (34)

Country Link
US (2) US7511057B2 (fr)
EP (1) EP1778686B9 (fr)
JP (1) JP4084836B2 (fr)
AP (1) AP2326A (fr)
AR (1) AR050692A1 (fr)
AT (1) ATE412652T1 (fr)
AU (1) AU2005273612B2 (fr)
BR (1) BRPI0514255A (fr)
CA (1) CA2576297C (fr)
CR (1) CR8918A (fr)
CU (1) CU23497A3 (fr)
CY (1) CY1108788T1 (fr)
DE (1) DE602005010714D1 (fr)
DK (1) DK1778686T3 (fr)
EA (1) EA012119B1 (fr)
EC (1) ECSP077232A (fr)
ES (1) ES2314690T3 (fr)
GE (1) GEP20104973B (fr)
GT (1) GT200500218A (fr)
HN (1) HN2005000418A (fr)
HR (1) HRP20080608T3 (fr)
IL (1) IL181047A (fr)
MA (1) MA28798B1 (fr)
MX (1) MX2007001759A (fr)
MY (1) MY140021A (fr)
NL (1) NL1029726C2 (fr)
NO (1) NO339320B1 (fr)
NZ (1) NZ552868A (fr)
PL (1) PL1778686T3 (fr)
PT (1) PT1778686E (fr)
SI (1) SI1778686T1 (fr)
SV (1) SV2006002193A (fr)
TN (1) TNSN07050A1 (fr)
WO (1) WO2006018718A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) * 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CA2642209A1 (fr) * 2006-02-09 2007-08-16 Pfizer Limited Composes triazolopyridine
JP5244369B2 (ja) * 2006-11-10 2013-07-24 富士フイルム株式会社 ５−アミノピラゾール誘導体の製造方法、アゾ色素
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
US8119658B2 (en) * 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
DK2303267T3 (da) * 2008-02-04 2013-09-02 Pfizer Ltd Polymorf form af et [1,2,4]-triazolo-[4,3-a]pyridinderivat til behandling af inflammatoriske sygdomme
US8498729B2 (en) 2008-08-29 2013-07-30 Smp Logic Systems Llc Manufacturing execution system for use in manufacturing baby formula
AU2009290811A1 (en) * 2008-09-12 2010-03-18 Universitatsklinikum Munster Means and methods for evaluating a therapy with a p38 map kinase inhibitor
JP2012517992A (ja) * 2009-02-17 2012-08-09 チェシ ファーマスーティシ エス．ピー．エイ． Ｐ３８ｍａｐキナーゼインヒビターとしてのトリアゾロピリジン誘導体
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
WO2010141796A2 (fr) 2009-06-05 2010-12-09 Cephalon, Inc. Préparation et utilisation de dérivés de 1,2,4-triazolo[1,5a]pyridine
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
US9024041B2 (en) 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
JP5973426B2 (ja) 2010-06-17 2016-08-23 レスピバート・リミテツド Ｐ３８ｍａｐｋ阻害剤を含む呼吸器用製剤
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
EP2578582A1 (fr) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napthtalèn-1-yl) urées comme inhibiteurs de la p38 MAP kinase
KR102057058B1 (ko) 2011-10-03 2019-12-18 레스피버트 리미티드 P38 map 키나제 저해제인 1-피라졸릴-3-(4-((2-아닐리노피리미딘-4-일)옥시)나프탈렌-1-일) 우레아
BR112014013178A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
SG10201604656YA (en) 2011-12-09 2016-07-28 Chiesi Farma Spa Kinase inhibitors
PT2788349T (pt) 2011-12-09 2017-02-02 Chiesi Farm Spa Inibidores de cinase
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
US20160016934A1 (en) 2013-03-14 2016-01-21 Respivert Limited Kinase inhibitors
HK1219101A1 (zh) * 2013-06-06 2017-03-24 奇斯药制品公司 作为p38map激酶抑制剂的[1，2，4]三唑并[4，3-a]吡啶的衍生物
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
KR20200067170A (ko) 2017-10-05 2020-06-11 풀크럼 쎄러퓨틱스, 인코포레이티드 FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3050525A (en) * 1960-12-14 1962-08-21 John B Bicking Certain derivatives of s-triazolo [4, 3-a]-pyridine
US3754887A (en) * 1969-05-05 1973-08-28 Du Pont Ureidopyrazoles defoliants
US4183854A (en) * 1976-11-10 1980-01-15 John Wyeth & Brother Limited Thiazole compound
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JP2627348B2 (ja) * 1990-03-16 1997-07-02 セイコー電子工業株式会社 ラインサーマルプリンタ
JPH11503110A (ja) 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
PL192628B1 (pl) 1996-04-23 2006-11-30 Vertex Pharma Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
WO1998024768A1 (fr) * 1996-12-03 1998-06-11 Banyu Pharmaceutical Co., Ltd. Nouveaux derives d'uree
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
CA2288787A1 (fr) 1997-05-22 1998-11-26 G.D. Searle And Co. Derives de pyrazole comme inhibiteurs de kinase p38
US5932576A (en) 1997-05-22 1999-08-03 G. D. Searle & Company 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
WO1998052940A1 (fr) 1997-05-22 1998-11-26 G.D. Searle And Co. PYRAZOLES SUBSTITUES UTILISES COMME INHIBITEURS DE p38 KINASE
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
NZ505844A (en) 1997-12-22 2003-10-31 Bayer Ag Inhibition of raf kinase using substituted heterocyclic ureas
EP1077971A1 (fr) 1998-05-14 2001-02-28 G.D. SEARLE & CO. PYRAZOLES A SUBSTITUTION 1,5-DIARYLE COMME INHIBITEURS DE LA PROTEINE p38 KINASE
WO2000005999A1 (fr) 1998-07-30 2000-02-10 Gulserene Dastur Mobilier resistant aux intemperies destine a etre utilise a l'exterieur
US6350744B1 (en) 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
JP2002534385A (ja) 1999-01-08 2002-10-15 スミスクライン・ビーチャム・コーポレイション 新規化合物
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6525046B1 (en) * 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
ATE372337T1 (de) * 2000-02-01 2007-09-15 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
US7978329B2 (en) 2000-08-02 2011-07-12 Honeywell International Inc. Portable scattering and fluorescence cytometer
EP1370559B1 (fr) * 2001-03-09 2006-04-19 Pfizer Products Inc. Triazolopyridines, agents anti-inflammatoires
DE60219793T2 (de) 2001-07-11 2008-01-24 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
JP2005519895A (ja) 2002-01-18 2005-07-07 ファルマシア・コーポレーション Ｐ３８阻害剤としての置換ピリダジノン
WO2003068223A1 (fr) 2002-02-11 2003-08-21 Bayer Corporation Urees aryliques a kinase de raf et activite inhibitrice d'angiogenese
JP4164031B2 (ja) 2002-02-14 2008-10-08 ファルマシア コーポレーション Ｐ３８ｍａｐキナーゼのモジュレータとしての置換されたピリジノン
AU2003224257A1 (en) 2002-04-09 2003-10-27 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
EP1511743A1 (fr) 2002-06-05 2005-03-09 Pharmacia Corporation Derives de pyrazols utilises comme inhibiteurs de la p38 kinase
JP2005538975A (ja) 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド ｐ３８ＭＡＰキナーゼ阻害薬としての３−（ヘテロ）アリールメトキシピリジン類およびそれらの類縁体
EP1601672B1 (fr) * 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines utilisees comme composes anti-inflammatoires
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
RU2357957C2 (ru) * 2003-03-03 2009-06-10 Эррэй Биофарма, Инк. Ингибиторы р38 и способы их применения
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor

Also Published As

Publication number Publication date
EP1778686A2 (fr) 2007-05-02
SV2006002193A (es) 2006-03-15
US7511057B2 (en) 2009-03-31
ATE412652T1 (de) 2008-11-15
PT1778686E (pt) 2008-12-26
IL181047A0 (en) 2007-07-04
NL1029726C2 (nl) 2007-08-14
NL1029726A1 (nl) 2006-02-14
US20060035922A1 (en) 2006-02-16
IL181047A (en) 2011-06-30
DK1778686T3 (da) 2009-01-12
ECSP077232A (es) 2007-03-29
BRPI0514255A (pt) 2008-06-03
MY140021A (en) 2009-11-30
CY1108788T1 (el) 2014-07-02
AR050692A1 (es) 2006-11-15
TNSN07050A1 (fr) 2008-06-02
DE602005010714D1 (de) 2008-12-11
NO339320B1 (no) 2016-11-28
AU2005273612A1 (en) 2006-02-23
AU2005273612B2 (en) 2010-10-14
AP2007003905A0 (en) 2007-02-28
GT200500218A (es) 2006-03-21
EP1778686B1 (fr) 2008-10-29
NO20071242L (no) 2007-05-07
CU23497A3 (es) 2010-03-25
JP4084836B2 (ja) 2008-04-30
NZ552868A (en) 2009-07-31
ES2314690T3 (es) 2009-03-16
CA2576297A1 (fr) 2006-02-23
WO2006018718A3 (fr) 2006-05-04
JP2008509901A (ja) 2008-04-03
US20090239899A1 (en) 2009-09-24
AP2326A (en) 2011-11-24
HRP20080608T3 (hr) 2008-12-31
EA200700219A1 (ru) 2007-08-31
HN2005000418A (es) 2009-12-07
US8076356B2 (en) 2011-12-13
MX2007001759A (es) 2007-04-20
CA2576297C (fr) 2011-01-25
EP1778686B9 (fr) 2009-07-08
CR8918A (es) 2007-04-02
PL1778686T3 (pl) 2009-04-30
WO2006018718A2 (fr) 2006-02-23
HK1105536A1 (en) 2008-02-15
SI1778686T1 (sl) 2009-02-28
GEP20104973B (en) 2010-04-26
EA012119B1 (ru) 2009-08-28

Similar Documents

Publication Publication Date Title
MA28798B1 (fr) Dérivés de triazolopyridinylsufanyle servant d'inhibiteurs de kinase MAP P38
MA29119B1 (fr) Derives de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
DK2039685T3 (da) Heterobicycliske forbindelser som P38-inhibitorer
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
NO20055590D0 (no) Kinaseinhiberende fosfonatanaloger
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
IS7505A (is) Pýrróló-tríazín anilín efnasambönd gagnleg sem kínasatálmar
ATE537843T1 (de) Neue kinase-hemmer
CY2015016I2 (el) Αναστολεις της κινασης τυροσινης του bruton
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
ATE443706T1 (de) Pyrrolotriazinverbindungen als kinaseinhibitoren
DE60117568D1 (de) Kondensierte pyrazol derivate als protein kinase inhibitoren
CY2007002I1 (el) Ω-καρβοξυαρυλυποκατεστημενες διφαινυλουριες σαν αναστολεις της raf κινασης
EP1937825A4 (fr) 4'-nucleosides modifies utiles comme agents antiviraux
MA28922B1 (fr) Nouveaux derives de phenylaminopyrimidine en tant qu'inhibiteurs de bcr-abl kinase
DE602005008661D1 (de) Michael-addierungs Zusammensetzungen
EP1746141A4 (fr) Composition d' epaississement
MA28543B1 (fr) Dérivés d'imidazole utilisés comme inhibiteurs tafia
ATE428708T1 (de) Neue phthalazinonderivate als aurora-a- kinaseinhibitoren
DE602004026905D1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
DE60203120D1 (de) Imidazopyridinone als p38 map kinase inhibitoren
ATE433449T1 (de) Kinaseinhibitoren
ZA200700923B (en) Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors